Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
The N‐methyl‐d‐aspartate receptor (NMDAR) antagonist (R,S)‐ketamine has robust antidepressant effects in depressed patients although it has detrimental side effects such as psychotomimetic and dissociative symptoms. (R,S)‐Ketamine is known to cause the expression of heat shock protein HSP‐70 (a marker for neuronal injury) in the retrosplenial cortex of rat brain, suggesting that the neuropathological changes may play a role in the detrimental side effects of (R,S)‐ketamine. This study was undertaken to examine whether (R,S)‐ketamine and its two enantiomers, (R)‐ketamine and (S)‐ketamine, causes the expression of HSP‐70 in the rat retrosplenial cortex after a single administration. The HSP‐70 immunohistochemistry in the rat brain was performed 24 h after intraperitoneal administration of saline (1 ml/kg), (+)‐MK‐801 (or dizocilpine: 1.0 mg/kg), (R,S)‐ketamine (100 mg/kg), (S)‐ketamine (25, 50, or 75, mg/kg), or (R)‐ketamine (25, 50, or 75 mg/kg). Marked expression of HSP‐70 immunoreactivity in the retrosplenial cortex was detected after administration of dizocilpine or (R,S)‐ketamine (100 mg/kg). Higher does (50 and 75 mg/kg) of (S)‐ketamine, but not low dose (25 mg/kg), caused expression of HSP‐70 in this region. In contrast, all doses of (R)‐ketamine did not induce the expression of HSP‐70 in this region. These findings suggest that marked expression of HSP‐70 in the retrosplenial cortex after a single dose of (R,S)‐ketamine or (S)‐ketamine may have detrimental side effects in the rat brain. Therefore, it is likely that (R)‐ketamine is a safer compound in humans than (R,S)‐ketamine and (S)‐ketamine. HighlightsNMDAR antagonists cause neuronal damages in the retrosplenial cortex.(R,S)‐Ketamine caused expression of HSP‐70 in the retrosplenial cortex(S)‐Ketamine caused expression of HSP‐70 in the retrosplenial cortex(R)‐Ketamine did not cause expression of HSP‐70.(R)‐Ketamine is a safer compound than (R,S)‐ketamine and (S)‐ketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718 · cited 1×
“Interestingly, it is reported that (S)-ketamine causes psychotomimetic and dissociative effects in depressed patients (Canuso et al., 2018; Daly et al., 2018; Singh et al., 2016).”
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598 · cited 1×
“The N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine exhibits rapid-acting and long-lasting antidepressant effects in treatment-resistant patients with major depressive disorder or bipolar disorder (Kishimoto et al., 2016; Newport et al., 2015; Xu et al., 2016).”
A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & for the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.0080 · Cited by 576 · cited 1×
“Although there remain concerns about the safety of repeated (R,S)-ketamine infusions, (R,S)-ketamine has been used widely as off-label treatment for mood disorders (Sanacora et al., 2017; Wilkinson et al., 2017; Zhang et al., 2016).”
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359 · cited 1×
“The N-methyl-D-aspartate receptor (NMDAR) antagonist (R,S)-ketamine exhibits rapid-acting and long-lasting antidepressant effects in treatment-resistant patients with major depressive disorder or bipolar disorder (Kishimoto et al., 2016; Newport et al., 2015; Xu et al., 2016).”
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationXu, Y., Hackett, M., Carter, G., Loo, C., Gálvez, V., Glozier, N., Glue, P., Lapidus, K., McGirr, A., Somogyi, A. A., et al. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv124 · Cited by 226
A REVIEW OF KETAMINE ABUSE AND DIVERSION: Review: Ketamine
Sassano-Higgins, S., Baron, D., Juarez, G., Esmaili, N., & Gold, M. (2016) · Depression and Anxiety · doi:10.1002/da.22536 · Cited by 204
Cited by
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“(R,S)-ketamine, (S)-ketamine, and (+)-MK-801 produced HSP-70 protein in the rat retrosplenial cortex whereas (R)ketamine did not produce HSP-70 protein in this brain region.(111) The reduction of parvalbumin (PV)-immunoreactivity in the PFC is associated with psychosis.”
MethodSelf-citationMicroglial ERK-NRBP1-CREB-BDNF Signaling in Sustained Antidepressant Actions of (R)-Ketamine
Yao, W., Cao, Q., Luo, S., He, L., Yang, C., Chen, J., Qi, Q., Hashimoto, K., & Zhang, J.-C. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01377-7 · Cited by 216
Self-citationYang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Self-citationChang, L., Zhang, K., Pu, Y., Qu, Y., Wang, S.-M., Xiong, Z., Ren, Q., Dong, C., Fujita, Y., & Hashimoto, K. (2019) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.04.008 · Cited by 176
Self-citationEsketamine for treatment resistant depression
Swainson, J., Thomas, R. K., Archer, S., Chrenek, C., MacKay, M.-A., Baker, G., Dursun, S., Klassen, L. J., Chokka, P., & Demas, M. L. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1640604 · Cited by 151
An update on ketamine and its two enantiomers as rapid-acting antidepressants
Zhang, K., & Hashimoto, K. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1554434 · Cited by 132
Self-citationZhang, K., Yang, C., Chang, L., Sakamoto, A., Suzuki, T., Fujita, Y., Qu, Y., Wang, S., Pu, Y., Tan, Y., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0733-x · Cited by 119
Self-citationZanos, P., Highland, J. N., Liu, X., Troppoli, T. A., Georgiou, P., Lovett, J., Morris, P. J., Stewart, B. W., Thomas, C. J., Thompson, S. M., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14683 · Cited by 82
Zhang, J., Qu, Y., Chang, L., Pu, Y., & Hashimoto, K. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz048 · Cited by 55
Self-citationXiong, Z., Fujita, Y., Zhang, K., Pu, Y., Chang, L., Ma, M., Chen, J., & Hashimoto, K. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.111904 · Cited by 49
Self-citationChen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Tian, J., Xie, Y., Ye, S., Hu, Y., Feng, J., Li, Y., Lou, Z., Ruan, L., & Wang, Z. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151965 · Cited by 10
Metadata
- Authors
- Tian, Z., Dong, C., Fujita, A., Fujita, Y., & Hashimoto, K.
- Venue
- Pharmacology Biochemistry and Behavior
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 172
- Pages
- 17-21
- ISSN
- 0091-3057 (ISSN-L)
- OpenAlex
- W2883574984
- Cited by
- 62
- References
- 14
- FWCI
- 3.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.